Search

Background: Little is known about the performance of abbreviated MRI (AMRI) for secondary surveillance of recurrent hepatocellular carcinoma (HCC) after curative treatment. Purpose: To evaluate the detection performance of AMRI for secondary surveillance of HCC after curative treatment. Study Type: Retrospective. Population: A total of 243 patients (183 men and 60 women; median age, 65 years) who underwent secondary surveillance for HCC using gadoxetic acid‐enhanced MRI after more than 2 year of disease‐free period following curative treatment, including surgical resection or radiofrequency ablation (RFA). Field Strength/Sequence: A 3.0 T/noncontrast AMRI (NC‐AMRI) (T2‐weighted fast spin‐echo, T1‐weighted gradient echo, and diffusion‐weighted images), hepatobiliary phase AMRI (HBP‐AMRI) (T2‐weighted fast spin‐echo, diffusion‐weighted, and HBP images), and full‐sequence MRI Assessment: Four board‐certified radiologists independently reviewed NC‐AMRI, HBP‐AMRI, and full‐sequence MRI sets of each patient for detecting recurrent HCC. Statistical Tests: Per‐lesion sensitivity, per‐patient sensitivity and specificity for HCC detection at each set were compared using generalized estimating equation. Results: A total of 42 recurred HCCs were confirmed in the 39 patients. The per‐lesion and per‐patient sensitivities did not show significant differences among the three image sets for either reviewer (P ≥ 0.358): per‐lesion sensitivity: 59.5%–83.3%, 59.5%–85.7%, and 59.5%–83.3%, and per‐patient sensitivity: 53.9%–83.3%, 56.4%–85.7%, and 53.9%–83.3% for NC‐AMRI, HBP‐AMRI, and full‐sequence MRI, respectively. Per‐lesion pooled sensitivities of NC‐AMRI, HBP‐AMRI, and full‐sequence MRI were 72.6%, 73.2%, and 73.2%, with difference of −0.6% (95% confidence interval: −6.7, 5.5) between NC‐AMRI and full‐sequence MRI and 0.0% (−6.1, 6.1) between HBP‐AMRI and full‐sequence MRI. Per‐patient specificity was not significantly different among the three image sets for both reviewers (95.6%–97.1%, 95.6%–97.1%, and 97.6%–98.5% for NC‐AMRI and HBP‐AMRI, respectively; P ≥ 0.117). Data Conclusion: NC‐AMRI and HBP‐AMRI showed no significant difference in detection performance to that of full‐sequence gadoxetic acid‐enhanced MRI during secondary surveillance for HCC after more than 2‐year disease free interval following curative treatment. Based on its good detection performance, short scan time, and lack of contrast agent‐associated risks, NC‐AMRI is a promising option for the secondary surveillance of HCC. Evidence Level: 3. Technical Efficacy: Stage 2. [ABSTRACT FROM AUTHOR]